Leviticus Cardio charges towards the market
A tiny Israeli company has beaten some of the biggest medtechs in the world to the wireless charging of heart pumps.
AACR 2019 – Foundation Medicine sets the scene for liquid biopsy approval
A study of a liquid biopsy and another looking at tumour mutational burden testing give early indications of Foundation’s approval strategy.
AACR 2019 – Guardant looks to its other liquid biopsy
With one cancer blood test established on the market Guardant is starting down the road to validating another – this time as a screening assay.
ACC 2019 – Low risk of patients being denied transcatheter aortic valves
The battle for dominance of the transcatheter aortic valve market has shifted to new territory. And once again, Edwards Lifesciences is winning.
ACC 2019 – Apple Heart Study posts decent results, but the next step will be harder
Another vast trial is on the cards for Apple’s ECG, and ought to yield more meaningful data.
ACC 2019 preview – Detection vs diagnosis: Irhythm and the Apple Watch
Will the Apple Heart Study allow early detection of arrhythmias, or drive the worried well to doctors unnecessarily? For Irhythm Technologies, either is a good outcome.
Smith & Nephew buys Osiris and insists it has appetite for more
The UK ortho and woundcare group might yet pounce on Nuvasive.
ACC 2019 preview – Medtronic seeks guidelines change with Tyrx data
A positive readout for Medtronic's Tyrx envelope could mean an extra $1,000 per cardiac implant in the company's pocket.
Guardant’s liquid biopsy matches tissue testing in lung cancer
Guardant gets a liquid biopsy trial win, but if it wants to drive sales it must get cancer societies on board.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.